Rocket Pharmaceuticals, Inc. Cash and Restricted Cash
Rocket Pharmaceuticals, Inc. (RCKT) had Cash and Restricted Cash of $225.85 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-10
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $225.85M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $50.95M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $78.90M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $77.31M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $225.85M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $50.95M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $78.90M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $77.31M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $34.18M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $51.17M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $165.00M 10-Q · filed 2026-08-10 |
| 2024-09-30 | $66.96M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $39.97M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $36.64M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $57.28M 10-K · filed 2026-02-26 |
| 2023-09-30 | $227.03M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $46.44M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $65.92M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $141.86M 10-K · filed 2025-02-27 |
| 2022-09-30 | $198.02M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $188.89M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $131.90M 10-Q · filed 2023-05-05 |
| 2021-12-31 | $234.04M 10-K · filed 2025-02-27 |
| 2021-09-30 | $246.98M 10-Q · filed 2022-11-04 |
| 2021-06-30 | $265.94M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $254.00M 10-Q · filed 2022-05-06 |
| 2020-12-31 | $298.67M 10-K · filed 2024-02-27 |
| 2020-09-30 | $83.79M 10-Q · filed 2021-11-05 |
| 2020-06-30 | $164.73M 10-Q · filed 2021-08-09 |
| 2020-03-31 | $192.04M 10-Q · filed 2021-05-10 |
| 2019-12-31 | $186.91M 10-K · filed 2023-02-28 |
| 2019-09-30 | $90.72M 10-Q · filed 2020-11-06 |
| 2019-06-30 | $66.36M 10-Q · filed 2020-08-05 |
| 2019-03-31 | $125.99M 10-Q · filed 2020-05-08 |
| 2018-12-31 | $112.79M 10-K · filed 2022-02-28 |
| 2018-09-30 | $39.72M 10-Q · filed 2019-11-08 |
| 2018-06-30 | $54.19M 10-Q · filed 2019-08-08 |
| 2018-03-31 | $171.34M 10-Q · filed 2019-05-09 |
| 2017-12-31 | $18.35M 10-K · filed 2021-03-01 |
| 2017-09-30 | $24.16M 10-Q · filed 2018-11-09 |
| 2017-06-30 | $28.30M 10-Q · filed 2018-08-14 |
| 2017-03-31 | $27.36M 10-Q · filed 2018-05-11 |
| 2016-12-31 | $9.66M 10-K · filed 2019-03-08 |
| 2015-12-31 | $15.49M 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |